Acorda Therapeutics, Inc. (NASDAQ:ACOR) – Investment analysts at Leerink Swann boosted their Q1 2018 EPS estimates for Acorda Therapeutics in a report issued on Wednesday. Leerink Swann analyst P. Matteis now anticipates that the biopharmaceutical company will earn $0.69 per share for the quarter, up from their previous estimate of $0.65. Leerink Swann currently has a “Market Perform” rating and a $18.00 target price on the stock.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.26). The firm had revenue of $141.07 million for the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.04) earnings per share.

WARNING: “Q1 2018 Earnings Forecast for Acorda Therapeutics, Inc. (ACOR) Issued By Leerink Swann” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/17/q1-2018-earnings-forecast-for-acorda-therapeutics-inc-acor-issued-by-leerink-swann.html.

Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus cut shares of Acorda Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $15.00 in a research report on Thursday. Raymond James Financial, Inc. cut shares of Acorda Therapeutics from a “market perform” rating to an “underperform” rating and upped their price target for the stock from $7.00 to $13.00 in a research report on Thursday. Janney Montgomery Scott set a $17.00 price target on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Thursday. Cowen and Company reaffirmed a “buy” rating and issued a $30.00 price target on shares of Acorda Therapeutics in a research report on Friday. Finally, ValuEngine raised shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Four analysts have rated the stock with a sell rating, ten have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Acorda Therapeutics currently has a consensus rating of “Hold” and an average target price of $21.51.

Shares of Acorda Therapeutics (NASDAQ ACOR) traded up $0.25 during trading hours on Thursday, reaching $17.25. 2,844,900 shares of the company traded hands, compared to its average volume of 942,245. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77.

Several large investors have recently bought and sold shares of ACOR. State of Wisconsin Investment Board acquired a new stake in Acorda Therapeutics during the second quarter worth about $630,000. Goldman Sachs Group Inc. increased its position in shares of Acorda Therapeutics by 306.8% during the second quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after acquiring an additional 403,467 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Acorda Therapeutics by 48.3% during the first quarter. AQR Capital Management LLC now owns 129,458 shares of the biopharmaceutical company’s stock valued at $2,719,000 after acquiring an additional 42,154 shares during the last quarter. Cambiar Investors LLC increased its position in shares of Acorda Therapeutics by 3.1% during the second quarter. Cambiar Investors LLC now owns 861,331 shares of the biopharmaceutical company’s stock valued at $16,968,000 after acquiring an additional 25,688 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Acorda Therapeutics by 29.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after acquiring an additional 541,418 shares during the last quarter.

In related news, major shareholder Scopia Capital Management Lp acquired 766,201 shares of the firm’s stock in a transaction on Tuesday, August 29th. The shares were acquired at an average cost of $19.23 per share, with a total value of $14,734,045.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.90% of the stock is currently owned by company insiders.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.